2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117765
    RS-5773 129173-57-5 98%
    RS-5773 is a calcium channel inhibitor and a diltiazem congener. RS-5773 has antianginal effect and does not cause excessive hypotension or depression of atrioventricular conduction .
    RS-5773
  • HY-117811
    (R,R)-MK 287 143490-81-7 98%
    (R,R)-MK 287 (L-680574) is a tetrahydrofuran derivative that potently inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with Ki values of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50=56 nM) and elastase release from PMNs (ED50=4.4 nM). (R,R)-MK 287 inhibits PAF-induced lethality in mice (ED50=0.8 mg/kg, po) and PAF-induced bronchospasm in guinea pigs (ED50=0.18 mg/kg).
    (R,R)-MK 287
  • HY-117814
    BMS-187308 153624-15-8 98%
    BMS-187308 is an orally active endothelin-A (ETA) antagonist, with Kis of 4.7 nM for ETA and 1.7 μM for ETB. BMS-187308 inhibits the pressor response to ET-1 (ED25: 1.2 µmol/kg; iv). BMS-187308 is a suitable tool for investigating the role of endothelin.
    BMS-187308
  • HY-117928
    BRL 55834 131899-25-7 98%
    BRL 55834 is an orally and potent potassium channel activator. BRL 55834 exhibits great bronchodilator potency but reduces tendency to lower arterial blood pressure. BRL 55834 has the potential to use as a bronchodilator.
    BRL 55834
  • HY-117966
    Bibn 140 145301-79-7 98%
    Bibn 140 is a pyridine derivative substituted with a benzene ring, which has high affinity (Ki: 12 nM) and selectivity for M2 mAChR receptors over M1 receptors.
    Bibn 140
  • HY-118014
    CAY10535 945716-28-9 98%
    CAY10535 is a FP and TP receptor inhibitor and can be used for research of cardiovascular diseases.
    CAY10535
  • HY-118019
    Scandenolide 23758-16-9 98%
    Scandenolide is a sesquiterpene lactone that can be found in Philippines medicinal plant Mikania cordata. Scandenolide inhibits leukotriene and platelet activating factor synthesis in leukocytes.
    Scandenolide
  • HY-118033
    SQ 30774 121995-36-6 98%
    SQ 30774 is a renin (renin) inhibitor. SQ 30774 has potent in vitro inhibitory effects in primates but not in rats, pigs, or dogs. And imidazolinol renin inhibitors also inhibit PRA and reduce arterial blood pressure in vivo.
    SQ 30774
  • HY-118044
    I-SAP 133538-58-6 98%
    I-SAP is a radioiodinated TXA2/PGH2 receptor antagonist. The bind between I-SAP and the receptors, is inhibited by the histidine modifying reagent diethyl-pyrocarbonate (DEPC).
    I-SAP
  • HY-118046
    GSK2163632A 1123163-20-1 98%
    GSK2163632A is a selective G protein-coupled receptor kinase (GRK) inhibitor that can be used as a probe for studying heart failure and Parkinson's disease. GSK2163632A potently inhibits GRK1 and GRK5, and also inhibits Rho-associated coiled-coil kinase (ROCK) and insulin-like growth factor receptor IGF-1R. GSK2163632A binds to GRK2 in a manner similar to Paroxetine (HY-122272).
    GSK2163632A
  • HY-118050
    L589420-0-2 1431-30-7 98%
    L589420-0-2 (L-420) is a sodium pump inhibitor with inhibitory activity in human erythrocytes. L589420-0-2 can regulate the concentration of intracellular sodium ions, thereby affecting the electrophysiological properties of cells. L589420-0-2 may also play an important role in the inhibition of cardiovascular diseases.
    L589420-0-2
  • HY-118084
    LS-104 368836-72-0 98%
    LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against JAK2, Bcr-Abl and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits JAK2 autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies.
    LS-104
  • HY-118094
    8-iso Prostaglandin E1 21003-46-3 98%
    8-iso Prostaglandin E1 (Ovinonic acid; 8-iso-PGE1) is a spasmodic agent in canine pulmonary veins and can also cause vasodilation.
    8-iso Prostaglandin E1
  • HY-118148
    UK-66914 113049-11-9 98%
    UK-66914, is a class III antiarrhythmic agent that specifically acts on the delayed rectifier potassium current (I_K). UK-66914 is designed to prolong action potential duration (APD) and increase cardiac refractory period, thereby potentially terminating the reentry mechanism in arrhythmias without affecting the serious side effects of antiarrhythmic drugs associated with other ion channels such as Na+ and Ca2+ currents.
    UK-66914
  • HY-118172
    PD-307243 313533-41-4 98%
    PD-307243 is a hERG channel activator. PD-307243 can be used for research of arrhythmias.
    PD-307243
  • HY-118202
    (-)-Gallopamil 36622-40-9 98%
    (-)-Gallopamil exerts a selective modulation of the fast voltage-dependent inactivation. (-)-Gallopamil inhibits efficiently Cav1.2 constructs formed by β-subunits (promoting fast voltage-dependent inactivation). (-)-Gallopamil also accelerates the voltage-dependent phase of ICa decay (as well as the voltage-dependent decay of Ba2+ currents). (-)-Gallopamil is promising for research of antiarrhythmics.
    (-)-Gallopamil
  • HY-118220
    EP 171 122089-44-5 98%
    EP 171 is a TP receptor agonist and human platelet activator. EP 171 can induce constriction of guinea pig trachea, and the constriction can be inhibited by the TP receptor antagonist EP 092. EP 171 binds to TP receptors on intact human platelets with an IC50 of 2.9 nM.
    EP 171
  • HY-118294
    15-OH Tafluprost 130209-78-8 98%
    15-OH Tafluprost, a prostaglandin F2a (PGF2a) analog, relieves endothelin-1 (ET-1)-induced optic nerve head (ONH) blood flow impairment and ET-1-induced contraction of isolated ciliary artery segments.
    15-OH Tafluprost
  • HY-118335
    Prazobind 107021-36-3
    Prazobind (SZL 49), a prazosin analog, is an irreversible α1-adrenoceptor antagonist. Prazobind competes for alpha 1-adrenoceptor binding sites with a similar potency (IC50 of 1 nM) in tissues enriched in both the alpha 1A (hippocampus) and alpha 1B (liver) subtypes. Prazobind partially inhibits the contractions of circular muscles, longitudinal muscles and smooth muscles of the spleen. Prazobind can be used for the study of blood pressure.
    Prazobind
  • HY-118339
    PF-4479745 1065110-43-1 98%
    PF-4479745 is a potent and selective 5-HT2C receptor agonist (EC50: 10 nM, ki: 15 nM). PF-4479745 can be used in the research of cardiovascular disease like hypertension.
    PF-4479745
Cat. No. Product Name / Synonyms Application Reactivity